在心力衰竭患者中比较高剂量与低剂量输入:2025年的元分析
Akshay Maharaj1, Sajay Bidhesi2, Sheneel Jaggernauth3
1Internal Medicine, Port of Spain General Hospital, Port of Spain, TTO.
Cureus
|October 17, 2025
概括
在心力衰竭患者中,更高剂量的Entresto (sacubitril/valsartan) 并没有显著改善左心室喷射率 (LVEF). 然而,高剂量的Entresto显示,大脑 natriuretic (NT-proBNP) 的N端前激素水平显著降低.
科学领域:
- 心脏病学和心血管研究
- 药理学和治疗学 药理学和治疗学
- 临床试验分析
背景情况:
- 恩特雷斯托 (萨库比特里尔/瓦尔沙坦) 是心力衰竭的关键治疗方法,心力衰竭的减少喷射率 (HFrEF).
- 它在不同剂量的有效性需要进一步的研究,以优化患者的结果.
- 了解剂量-反应关系对于完善HFrEF管理策略至关重要.
研究的目的:
- 为了比较高剂量与低剂量Entresto在慢性心力衰竭患者中的有效性.
- 评估不同剂量的Entresto对关键心血管结果的影响.
- 通过元分析综合随机对照试验的证据.
主要方法:
- 对PubMed,ClinicalTrials和Cochrane数据库进行系统的文献搜索.
- 九项随机对照试验的元分析,涉及4011名HFrEF患者.
- 主要结局包括心力衰竭住院,死亡率,LVEF,NT-proBNP,NYHA类和血压.
主要成果:
- 在低剂量和高剂量Entresto组之间,左心室喷射率 (LVEF) 的改善没有统计学上显著的差异.
- 随着更高的Entresto剂量,观察到大脑天然尿素 (NT-proBNP) N-终端前激素水平的统计学显著降低.
- 更高的Entresto剂量与更大的NT-proBNP减少有关,这表明心脏应激和功能有所改善.
结论:
- 高剂量的Entresto与较低剂量相比没有显著的LVEF益处,但有效降低了NT-proBNP水平.
- 这些发现支持Entresto在管理HFrEF方面的潜在剂量依赖益处,特别是关于心脏压力标志物的益处.
- 需要进一步的大规模研究来确认长期的临床影响,并优化Entresto的剂量策略.
相关概念视频
01:30Heart Failure V: Medical Management
215
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
215
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
928
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
928
01:26Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
01:22Heart Failure Drugs: β-Blockers
760
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
760
01:30Heart Failure IV: Classification and Diagnostic Evaluation
317
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
317
01:22Heart Failure Drugs: Diuretics
796
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
796